Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

NCT05441826 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor change

Conditions

Minimal Change Disease
Focal Segmental Glomerulosclerosis

Interventions

DRUG: VB119

Sponsor

Tenet Medicines